Neogenomics receives Investment Bank Analyst Rating Update
VANCOUVER, British Columbia, Aug. 05, 2022 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTCQB: NBMFF) Initiated Detailed Design of the Silicon Anode Commercial Plant and Completed Basic...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Many investors look for anomalies or systematic patterns—often described as influences due to seasonality—to beat the market. One of these is the January effect which suggests that...
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. It offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.